Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Total Debt (2021 - 2025)

Kezar Life Sciences' Total Debt history spans 5 years, with the latest figure at $6.7 million for Q3 2025.

  • For Q3 2025, Total Debt fell 35.17% year-over-year to $6.7 million; the TTM value through Sep 2025 reached $6.7 million, down 35.17%, while the annual FY2024 figure was $10.3 million, 2.57% up from the prior year.
  • Total Debt for Q3 2025 was $6.7 million at Kezar Life Sciences, down from $7.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $10.3 million in Q4 2024 and bottomed at $6.7 million in Q3 2025.
  • The 5-year median for Total Debt is $9.9 million (2022), against an average of $9.6 million.
  • The largest annual shift saw Total Debt grew 2.57% in 2024 before it tumbled 35.17% in 2025.
  • A 5-year view of Total Debt shows it stood at $9.6 million in 2021, then increased by 2.2% to $9.8 million in 2022, then increased by 2.39% to $10.1 million in 2023, then increased by 2.57% to $10.3 million in 2024, then plummeted by 35.58% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Total Debt are $6.7 million (Q3 2025), $7.9 million (Q2 2025), and $9.1 million (Q1 2025).